Amryt Pharma PLC’s (LON:AMYT) flagship Lojuxta drug will soon be available in all five of the EU’s largest markets after French officials agreed to reimburse patients receiving the ‘bad’ cholesterol treatment.
The drug is expected to be made available to French patients suffering from the rare condition – known in the medical sphere as Homozygous Familial Hypercholesterolaemia (HoFH) – from early next year.
The approval means that Lojuxta is available across all five of the EU's major markets – France, the UK, Italy, Germany and Spain.
“A clear aim in continuing the positive momentum in Lojuxta revenues is to ensure reimbursement in our core territories,” said chief executive Joe Wiley.
“Following closely on from our recent approval with the NHS in England, where we have already started treating patients, we are now very pleased to be able to make Lojuxta available to adult HoFH patients in France.”
HoFH is a rare life-threatening disorder that causes abnormally high levels of low-density lipoprotein (LDL) cholesterol.
Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.